Open an account

Lexeo Therapeutics

LXEO · NASDAQ

$3.02+$0.26 (+9.42%)TodayMarket closed ·
Prev close $2.76

About LXEO

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 59 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Employees
59
Headquarters
New York City, New York
Listed
Nov 3, 2023
Sector
Health Care
Industry
Biotechnology
Website
lexeotx.com

LXEO key statistics

Market cap
247.91M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.11M
Volume
1.28M
Open price
$2.76
High today
$3.06
Low today
$2.71
52 Week high
$10.99
52 Week low
$2.55

Lexeo Therapeutics (LXEO) at a glance

As of Oct 20, 2026, Lexeo Therapeutics (LXEO) shares are priced at $3.02, giving the company a market cap of 247.91M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.71 and $3.06. The current price is 11.4% above the day's low and 1.1% below its high.

Volume so far is 1.28M shares, below the average of 2.11M shares a day.

Over the past year Lexeo Therapeutics has ranged from $2.55 to $10.99, and now sits 6% of the way up that range.

Lexeo Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.30 per share against an estimate of -$0.2907.

The average analyst price target is $21.99, 628.0% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $21.99
Low
$15.15
Now
$3.02
High
$31.50

LXEO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 18.8% on average.

  1. Q3 FY24: reported -$0.89 per share against an estimate of -$0.6921
  2. Q4 FY24: reported -$0.78 per share against an estimate of -$0.8233
  3. Q1 FY25: reported -$0.99 per share against an estimate of -$0.799
  4. Q2 FY25: reported -$0.60 per share against an estimate of -$0.6936
  5. Q3 FY25: reported -$0.33 per share against an estimate of -$0.5304
  6. Q4 FY25: reported -$0.27 per share against an estimate of -$0.3208
  7. Q1 FY26: reported -$0.25 per share against an estimate of -$0.3196
  8. Q2 FY26: reported -$0.30 per share against an estimate of -$0.2907

LXEO news

  • Press releasePRNewswire

    Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

  • Press releaseGlobe Newswire

    Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

  • Vandana Singh

    Why Is Lexeo Therapeutics Stock Gaining Monday?

  • Press releaseGlobe Newswire

    Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

  • Press releaseGlobe Newswire

    Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

  • Press releaseGlobe Newswire

    Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

  • Press releaseGlobe Newswire

    Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

  • Press releaseGlobe Newswire

    Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference

Similar companies

Companies in the same industry as Lexeo Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.